Key Highlights
- Net loss per share was USD 0.18 against an estimate of a USD 0.27 loss.
- Net loss was USD 34.44 million, compared with USD 56.76 million.
- Research and development expense was USD 22.61 million, compared with USD 40.52 million.
- Cash and cash equivalents were USD 85.65 million at September 30, 2026.
Neumora Therapeutics (NASDAQ:NMRA) reported a net loss of USD 34.44 million for the third quarter of 2026, compared with USD 56.76 million in the third quarter of 2025. The net loss per share was USD 0.18, compared with USD 0.35, against an estimate of a USD 0.27 loss.
The Quarterly Report did not state a Revenue figure for the period.
Operating Expenses
Research and development expense was USD 22.61 million, compared with USD 40.52 million. General and administrative expense was USD 10.80 million, compared with USD 12.18 million. The prior-year quarter included acquired in-process Research and Development expense of USD 5.00 million, with none in the current quarter. Total operating expenses, which equal the loss from operations, were USD 33.41 million, compared with USD 57.70 million.
Interest income was USD 0.81 million, compared with USD 1.69 million, and interest expense was USD 1.83 million, compared with USD 0.75 million.
Nine-Month Results
For the nine months ended September 30, 2026, the net loss was USD 130.98 million, compared with USD 177.48 million, and the net loss per share was USD 0.71, compared with USD 1.10. Research and development expense was USD 90.50 million, compared with USD 131.40 million, and general and administrative expense was USD 37.97 million, compared with USD 46.28 million. Total operating expenses were USD 128.46 million, compared with USD 182.68 million.
Balance Sheet
Cash and cash equivalents were USD 85.65 million at September 30, 2026, compared with USD 182.53 million at December 31, 2025. Prepaid expenses and other current Assets were USD 9.09 million, compared with USD 8.01 million, and total current assets were USD 94.75 million, compared with USD 190.54 million. Total assets were USD 95.05 million, compared with USD 191.05 million.
The company is advancing NMRA-511, a vasopressin 1a receptor antagonist for the treatment of agitation associated with dementia due to Alzheimer's disease, and a Phase 1 multiple-ascending dose study of NMRA-898, a muscarinic acetylcholine receptor subtype 4 positive allosteric modulator for the treatment of schizophrenia. It is also developing NMRA-215, an oral NLRP3 inhibitor for the treatment of obesity and cardiovascular risk. The filing states that the company acquired BlackThorn for its in-process research and development programs, including navacaprant, an antagonist of the kappa opioid receptor for major depressive disorder.
The company states that it has incurred net losses and negative cash flows from operations since inception and had an accumulated Deficit of USD 1,315.1 million at September 30, 2026. Weighted-average shares outstanding were 187.90 million for the quarter, compared with 161.84 million.
Neumora Therapeutics Q3 2026 Earnings: Key Takeaways
Neumora Therapeutics reported a third quarter 2026 net loss of USD 34.44 million and a loss per share of USD 0.18. Cash and cash equivalents were USD 85.65 million at September 30, 2026.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...